Celularity Inc. received notice of non-compliance with Nasdaq due to delayed financial report filings, seeking a compliance plan by September 4.
Quiver AI Summary
Celularity Inc. announced on August 25, 2026, that it received a notification from Nasdaq regarding its non-compliance with Listing Rule 5250(c)(1) due to its failure to file Quarterly Reports for the periods ending March 31 and June 30, 2026. Nasdaq has requested that the company submit a plan for regaining compliance by September 4, 2026, with a grace period lasting until November 16, 2026. Despite this notification, there is no immediate impact on the trading of the company's stock, which continues to be listed under the symbol "CELU." The company is actively working to complete and file the overdue reports.
Potential Positives
- The notification does not have an immediate effect on the listing or trading of the Company's common stock, allowing normal trading to continue.
- The Company is actively working on completing and filing its delayed Quarterly Reports, demonstrating a commitment to compliance and transparency.
- The Company has a clear timeline to submit a plan for regaining compliance, showing proactive efforts to address the situation.
Potential Negatives
- The company is currently not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the failure to file necessary quarterly reports, indicating potential operational and financial management issues.
- Receiving a notification from Nasdaq increases scrutiny on the company, which may affect investor confidence and the company's public image.
- The company has a deadline to submit a plan for regaining compliance, which adds pressure and uncertainty to its future operations and financial reporting.
FAQ
What compliance issue did Celularity Inc. face?
Celularity Inc. received a notification for not filing its Quarterly Reports on Form 10-Q for two periods, violating Nasdaq Listing Rule 5250(c)(1).
What action is Nasdaq requiring from Celularity Inc.?
Nasdaq has requested that Celularity submit a plan to regain compliance by September 4, 2026.
Will Celularity's stock still trade on Nasdaq?
Yes, Celularity’s common stock continues to trade on the Nasdaq Capital Market under the symbol “CELU.”
How long does Celularity have to regain compliance?
Celularity has until November 16, 2026, to regain compliance, as Nasdaq allows a maximum of 180 days for exceptions.
What does Celularity specialize in?
Celularity Inc. focuses on developing placental-derived cellular therapies in the field of regenerative and cellular medicine.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CELU Hedge Fund Activity
We have seen 14 institutional investors add shares of $CELU stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 99,054 shares (+inf%) to their portfolio in Q2 2026, for an estimated $59,224
- BLACKROCK, INC. removed 51,142 shares (-40.1%) from their portfolio in Q2 2026, for an estimated $30,577
- VALMARK ADVISERS, INC. removed 49,983 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $29,884
- HRT FINANCIAL LP added 43,807 shares (+342.7%) to their portfolio in Q2 2026, for an estimated $26,192
- JANE STREET GROUP, LLC added 28,713 shares (+inf%) to their portfolio in Q2 2026, for an estimated $17,167
- GEODE CAPITAL MANAGEMENT, LLC removed 23,926 shares (-12.5%) from their portfolio in Q2 2026, for an estimated $14,305
- VIRTU FINANCIAL LLC added 18,697 shares (+inf%) to their portfolio in Q2 2026, for an estimated $11,178
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission.
Nasdaq has requested that the Company submit its plan to regain compliance by September 4, 2026. Any exception granted by Nasdaq will be limited to a maximum of 180 calendar days from the prescribed due date of the initial delinquent filing, or until November 16, 2026.
The notification has no immediate effect on the listing or trading of the Company’s common stock, which continues to trade on the Nasdaq Capital Market under the symbol “CELU.” The Company is working to complete and file both Quarterly Reports on Form 10-Q as soon as practicable
About Celularity
Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing placental-derived cellular therapies. For more information, visit www.celularity.com .
Forward Looking Statements
This press release contains forward-looking statements regarding the Company’s ability to complete its delayed filings and regain compliance with Nasdaq’s continued listing requirements. Actual results may differ materially due to risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by law.
